There needs to be more transparency in drug pricing — including looking at the middlemen — but when it comes to the controversy about Mylan’s pricing of its EpiPen, the company still has a lot of questions to answer
There needs to be more transparency in drug pricing — including looking at the middlemen — but when it comes to the controversy about Mylan’s pricing of its EpiPen, the company still has a lot of questions to answer
In a recent article in the Bristol Herald Courier, David Balto gives a great summary of the problems with the pharmacy benefit management industry, such
In a recent article at BenefitsPRO, Dan Cook talks about the movement to have employers “rise up and fight their own battles with the drug
“Today, one in four Americans who need prescription drugs struggle to afford them — one in four,” president Joe Biden. The last two administrations have
Lowcost Pharmacy Benefit Management
877.877.5711
info@arayarx.com
PO Box 460
Latham, NY 12110